CHICAGO--(BUSINESS WIRE)--Jun 4, 2012-- GE Healthcare today announced results of a unique partnership with Fred Hutchinson Cancer Research Center and the Center for Sustainable Health at Arizona State University. This partnership is directed at identifying areas in oncology where diagnostics could provide high value through reducing costs, while at the same time maintaining or improving patient outcomes. Focusing on colorectal cancer, researchers brought leading US experts in colorectal cancer care, health policy, and insurance to discuss opportunities for diagnostics to improve clinical care.
Following the recommendations of this expert panel, the team created a decision-based model to estimate the potential cost-effectiveness of biomarker-directed use of bevacizumab versus current practice in the first-line treatment of metastatic colorectal cancer.1 Results from the model, presented by Kristin Berry, Ph.D. and colleagues at Fred Hutchinson Cancer Research Center, estimated that biomarker-directed therapy could save an average of $33,000 and provide a gain of four quality-adjusted progression-free days of survival per patient. These results were driven by targeting anti-angiogenic therapy to patients shown to respond and discontinuing the addition of bevacizumab to standard chemotherapy regimens in biomarker-identified non-responders. Dr. Berry noted that, "The impact of not treating with bevacizumab, those identified as non-responders to anti-angiogenic therapy, suggests the value of continued research to develop and validate such a biomarker." "We recognize that early economic evaluations of potential biomarker-guided treatment pathways can provide useful preliminary information to developers, clinicians and payers," said Ger Brophy, Head of New Product Development at GE Healthcare, Medical Diagnostics.
"Decision modeling, as outlined in this study, suggests that a biomarker capable of identifying responders to bevacizumab with high specificity and moderate sensitivity could be used to inform clinical decision-making. The development of such a marker may help improve the use of beneficial, yet highly expensive treatments - something that molecular imaging may be able to provide." For this study, researchers developed a decision model using the US healthcare system perspective. The model was designed to estimate the incremental impact on costs, progression-free survival and quality-adjusted progression-free survival of using a biomarker to target the addition of bevacizumab to only those patients who showed biomarker response to anti-angiogenic treatment (biomarker-directed therapy) compared to adding bevacizumab to the therapy provided to all eligible patients, as is current practice.
About GE Healthcare GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our web site at www.gehealthcare.com.
For our latest news, please visit http://newsroom.gehealthcare.com 1 Berry K, Bensink M, Musa Z et al. Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer. Poster presented at 2012 Annual Meeting of the American Society of Clinical Oncology, June 1-4, Chicago, Ill.
CONTACT: GE Healthcare Scott Lerman, 609-514-6346 Mobile: 609-937-9253 Scott.firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA ARIZONA ILLINOIS INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS ONCOLOGY COMMUNICATIONS PUBLIC RELATIONS/INVESTOR RELATIONS GENERAL HEALTH SOURCE: GE Healthcare Copyright Business Wire 2012 PUB: 06/04/2012 08:00 AM/DISC: 06/04/2012 08:00 AM http://www.businesswire.com/news/home/20120604005490/